Core Viewpoint - 康宁杰瑞制药-B expects to achieve a profit of no less than RMB 20 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 44.9 million in the same period of 2024, indicating a turnaround from loss to profit driven by milestone revenues from three licensing collaborations and sales from commercialized products [1][1][1] Group 1 - Following the announcement, 康宁杰瑞制药-B's stock rose over 3%, currently trading at HKD 9.42 with a transaction volume of HKD 10.1093 million [1][1] - 广发证券 highlights the company's robust proprietary technology platform in ADC, bispecific antibodies, and multifunctional protein engineering, suggesting a strong differentiation in its internal pipeline [1][1] - The company’s pipeline includes various anti-tumor drugs at different stages of development, showcasing its potential for growth in the biopharmaceutical sector [1][1]
康宁杰瑞制药-B盈喜后涨超3% 预计中期利润不少于2000万元